Denintuzumab mafodotin, also known as SGN-CD19A, SGN-19A, Anti-CD19-mafodotin and Anti-CD19-mcMMAF, is an Antibody-drug Conjugate targeting CD19, a protein expressed broadly on B-cell malignancies. The drug is being developed by Seattle Genetics.
Denintuzumab mafodotin is comprised of an anti-CD19 monoclonal antibody linked to a synthetic cytotoxic cell-killing agent, monomethyl auristatin F (MMAF). This Antibody-drug Conjugate is designed to be stable in the bloodstream, and to release its cytotoxic agent MMAF upon internalization into CD19-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.
SGN-CD19A is being evaluated in two ongoing phase I clinical trials for the treatment of patients with B-cell ALL and aggressive Non-Hodgkin’s lymphoma (NHL) as well as a phase II clinical trial in relapsed or refractory Diffuse large B cell lymphoma (DLBCL), lymphoblastic leukemia and follicular lymphoma.
- Safety Study of SGN-CD19A for Leukemia and Lymphoma (NCT01786096)
- A Safety Study of SGN-CD19A for B-Cell Lymphoma (NCT01786135)
- Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma (NCT02592876)
Illustration: Structure of denintuzumab mafodotin Courtesy: WHO – World Health Organization.